Table 4.

Overview of current clinical studies of MAGL inhibitor 21 (ABX-1431).

Study phase	Status	Study title	Condition or disease	Intervention/treatment
Phase 1	Active, not recruiting	A randomized, placebo-controlled, optimized titration study of ABX-1431 in adult patients with peripheral neuropathic pain.	Post herpetic neuralgia Diabetic peripheral neuropathy Small fibre neuropathy Post-traumatic neuralgia	Drug: ABX-1431 Drug: placebo oral capsule
Phase 1	Completed	A double-blind, placebo-controlled, crossover study to evaluate the safety and efficacy of ABX-1431 in patients with central pain.	Neuromyelitis optical spectrum disorder Transverse myelitis Multiple sclerosis Longitudinally extensive transverse myelitis	Drug: ABX-1431 HCl Drug: placebo
Phase 1	Completed	An fMRI study in healthy volunteers to investigate the effects of ABX-1431 on experimental hyperalgesia and its neural correlates.	Pain	Drug: ABX-1431 Drug: placebo
Phase 1	Terminated (recruitment challenges)	A single-dose study to evaluate the effects of ABX-1431 on gastric accommodation and nutrient volume tolerance in patients with functional dyspepsia.	Dyspepsia	Drug: ABX-1431 Drug: placebo
Phase 1	Completed	A randomized, placebo-controlled, single-dose crossover study of ABX-1431 HCl in adult patients with tourette syndrome (TS) and chronic motor tic disorder.	Tourette syndrome Chronic motor tic disorder	Drug: ABX-1431 Drug: placebo comparator
Phase 2	Recruiting	A randomized, placebo-controlled study of ABX-1431 in adult patients with tourette syndrome or chronic motor tic disorder.	Tourette syndrome Motor tic disorder	Drug: ABX-1431 Drug: placebo